Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;20(2):160-5.
doi: 10.4103/0971-6866.142884.

FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from India

Suchitra Swaminathan  1 , Swati Garg  2 , Manisha Madkaikar  2 , Maya Gupta  2 , Farah Jijina  3 , Kanjaksha Ghosh  2
Affiliations

FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from India

Suchitra Swaminathan et al. Indian J Hum Genet. 2014 Apr.

Abstract

Background: Acute promyelocytic leukemia (APL) with t (15;17) is a distinct category of acute myeloid leukemia (AML) and is reported to show better response to anthracyclin based chemotherapy. A favorable overall prognosis over other subtypes of AML has been reported for APL patients but still about 15% patients relapse.

Methods: This study evaluated the presence of Famus like tyrosine kinase-3 (FLT3) and nucleophosmin-1 (NPM1) gene mutations in a cohort of 40 APL patients. Bone marrow/peripheral blood samples from patients at the time of diagnosis and follow-up were processed for immunophenotyping, cytogenetic markers and isolation of DNA and RNA. Samples were screened for the presence of mutations in FLT3 and NPM1 genes using polymerase chain reaction followed by sequencing.

Results: Frequency of FLT3/internal tandem duplication and FLT3/tyrosine kinase domain was found to be 25% and 7% respectively. We observed a high frequency of NPM1 mutation (45%) in the present population of APL patients.

Keywords: Acute promyelocytic leukemia; famus like tyrosine kinase-3; nucleophosmin-1.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Similar articles

See all similar articles

Cited by

References

    1. Stock W, Najib K, Moser BK, Powell BL, Holowka N, Gulati K, et al. High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710) J Clin Oncol. 2008;26:374. - PubMed
    1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8. - PubMed
    1. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood. 1992;79:543–53. - PubMed
    1. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t (15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675–84. - PubMed
    1. Parmar S, Tallman MS. Acute promyelocytic leukaemia: A review. Expert Opin Pharmacother. 2003;4:1379–92. - PubMed